文档介绍：® 世界华人消化杂志 2010年6月28日; 18(18): 1932-1935
wcjd@ ISSN 1009- 14-1260/R
临床经验 CLINICAL PRACTICE
阿德福韦酯联合拉米夫定抗病毒治疗慢性乙型肝炎32例
熊英
■背景资料熊英, 南昌大学第一附属医院感染科江西省南昌市 330006 the treatment group than in the control group (P
通讯作者: 熊英, 主任医师, 330006, 江西省南昌市, 南昌大学第
核苷( 酸) 类似物< ). The overall response rate, as revealed by
是目前获得国家一附属医院感染科. lixueqingd@
食品与药物管理收稿日期: 2010-03-29 修回日期: 2010-05-13 HBV DNA load, was significantly higher in the
接受日期: 2010-05-18 在线出版日期: 2010-06-28
局(SFDA)批准可 treatment group than in the control group at 12
用于治疗CHB的 mo (P < ).
抗HBV药物, 具有
明显抑制病毒复 Treatment of chronic hepatitis
制的作用, 长期用 CONCLUSION: ADV bination with LAM
药多数病例能达 B with adefovir dipivoxil in can increase the response rate and ALT normal-
bination with lamivudine: ization rate in CHB patients.
分病例完全清除 an analysis of 32 cases
病毒的目的, 受到 Key Words: Adefovir dipivoxil; Lamivudine; Chronic
国内外学者的广
hepatitis B; Antiviral therapy
泛关注. 拉米夫定 Ying Xiong
(Lamivudine, LVD)
是临床上常用的 Xiong Y. Treatment of chronic hepatitis B with adefovir
Ying Xiong, Department of Infectious Diseases, the First
治疗CHB抗HBV dipivoxil bination with lamivudine: an analysis
Affiliated Hospital of Nanchang University, Nanchang
药物, 单独用药临 of 32 cases. Shijie Huaren Xiaohua Zazhi 2010; 18(18):
330006, Jiangxi Province, China
床效果不理想, 但 1932-1935
Correspondence to: Ying Xiong, Department of Infec-
联